Last updated: June 19, 2026
Covis Pharma GmbH sued Eugia Pharma Specialties Ltd. over an FDA-generic entry tied to Covis’s branded product(s), with the dispute framed as a patent infringement case under the Hatch-Waxman framework. The docket caption indicates a Delaware federal filing on Jan. 5, 2021, docket number 1:21-cv-00003. No additional, case-specific record details (asserted patents, venue/judge, substantive allegations, motion outcomes, or settlement terms) are included in the information provided, so a complete litigation-position and merits analysis cannot be produced.
What does Covis Pharma GmbH v. Eugia Pharma Specialties Ltd. (1:21-cv-00003) claim?
Featured snippet: The matter is a federal patent infringement action connected to an FDA small-molecule generic entry under Hatch-Waxman, brought by Covis against Eugia. The case number and parties are identified, but asserted patents, product, and claims-in-suit are not.
Which patents are asserted in 1:21-cv-00003?
- Not stated in the provided inputs.
- A litigation analysis requires the specific listed patents (U.S. numbers) and the “claims for which relief is requested.”
What regulatory act underpins the infringement theory?
- Typical Hatch-Waxman structure is a claim that the generic’s ANDA (or amendment) includes a Paragraph IV certification and that the generic product infringes one or more Orange Book listed patents.
- The specific ANDA number, FDA submission date, and Paragraph IV certifications are not provided.
What is the procedural posture in Covis v. Eugia, 1:21-cv-00003?
Featured snippet: The record details needed to determine posture (complaint date, answer, Markman, claim construction orders, summary judgment, trial schedule, and disposition) are not included in the provided inputs.
Timeline of known milestones
- Jan. 5, 2021: Case filed (per docket number/caption reference: 1:21-cv-00003).
- Remaining events: not available in the provided inputs.
Key procedural events to locate in the docket (not supplied)
- Initial complaint and patent list
- Eugia’s answer and invalidity/unenforceability defenses
- Any Rule 12 or venue/joinder motions
- Claim construction (Markman) proceedings
- Daubert or expert reports schedule
- Summary judgment rulings
- Scheduling order modifications
- Final judgment or dismissal
- Settlement and consent judgment entries
How strong is Covis’s patent estate in 1:21-cv-00003?
Featured snippet: Strength assessment depends on the specific asserted patent claims, their priority dates, remaining term, prosecution history, and validity arguments asserted by Eugia. Those inputs are not provided.
What factors determine strength in a Hatch-Waxman case?
- Remaining patent term at the time of the ANDA submission
- Claim scope breadth vs. known design-around routes
- Anticipation/obviousness risks based on cited prior art
- Enablement and written description issues
- Obviousness based on combinations
- Prosecution history estoppel and doctrine of equivalents limitations
What “strength” metrics would be used
- Asserted claim set and dependent claim coverage
- PTAB inter partes review history (if any)
- Litigation history for the same family or same claims
- Claim construction findings (if any)
- Summary judgment outcomes (if any)
None of these are determinable from the provided information.
Which generic entry risks exist for Eugia in 1:21-cv-00003?
Featured snippet: Generic entry timing risk is driven by (1) Orange Book listed patents and (2) any court-ordered exclusivity, injunctions, or settlement-triggered carveouts. The Orange Book and the settlement/injunction status are not included.
What determines “launch risk”
- Whether the court enjoins the ANDA launch pending patent expiration
- Whether any patents are found not infringed or invalid
- Whether the case ends in a settlement with an agreed launch date
- Whether remaining patents (not asserted) still block entry
What would be needed to quantify risk
- ANDA status (approved date, tentative approval)
- The patents-in-suit and their expiration dates
- The disposition date and any “skinny label” constraints
Those details are not provided.
What is the Orange Book status of Covis’s product(s) at issue?
Featured snippet: Orange Book status requires the branded NDA number, listed patent numbers, and expiration dates. Those data are not supplied.
What Orange Book elements matter in litigation analysis
- Patent numbers listed for the NDA
- Patent expiration and any pediatric exclusivity
- Method-of-use vs. formulation vs. device patents
- Whether the generic filed Paragraph IV certifications against those listed patents
Without the NDA/patent list, the Orange Book status cannot be stated.
What settlement agreements or injunctions resolved Covis v. Eugia, 1:21-cv-00003?
Featured snippet: Settlement terms and any injunction orders are not included in the provided inputs.
What to extract from the docket (not supplied)
- Consent judgment entries
- Stipulated dismissal with prejudice/without prejudice
- Modified launch dates (often tied to partial patent waivers)
- Covenant-not-to-sue terms and “final launch” definitions
- Any requirements for label changes or carveouts
How does Covis’s position compare with other litigations against Eugia?
Featured snippet: Comparative analysis requires a list of other cases, asserted patents, and outcomes. None are provided.
What comparison would cover
- Repeat asserted patent families
- Consistency of claim construction outcomes
- Settlement patterns (typical launch dates and carveout scope)
- Strength profile based on win-loss record by patent family
No case set is provided.
Commercial and regulatory impact of 1:21-cv-00003 on Eugia’s business
Featured snippet: Commercial impact depends on the revenue at stake for the branded product, the exclusivity window remaining, and the generic product’s intended launch timing. Product identity, ANDA details, and disposition outcome are not provided.
What a full impact model would require
- Branded product peak sales and current sales
- FDA approval status of Eugia’s generic
- Enjoined vs. permitted launch status
- Expected market entry date based on court or settlement terms
- Channel access and formulary dynamics
Those inputs are not provided.
Key Takeaways
- Covis Pharma GmbH v. Eugia Pharma Specialties Ltd., No. 1:21-cv-00003, is a Delaware federal patent infringement dispute tied to FDA generic entry, filed Jan. 5, 2021.
- A litigation summary with actionable analysis cannot be completed without the case-specific docket substance: asserted patents, accused product/ANDA, claim construction and motion outcomes, and any settlement or judgment entries.
- No Orange Book, exclusivity, injunction, or settlement facts are available in the provided information, so exclusivity-timing and launch-risk assessments are not determinable.
FAQs
- What is the typical Hatch-Waxman structure in cases like Covis v. Eugia (1:21-cv-00003)?
- How do claim construction rulings usually change infringement outcomes in Paragraph IV litigation?
- What are the most common defenses (invalidity/unenforceability) raised by generic filers in Hatch-Waxman suits?
- How do settlements in patent cases usually affect generic “first launch” dates and labeling?
- What categories of patents (method-of-use vs. formulation) most often drive remaining exclusivity after an ANDA challenge?
References
- United States District Court for the District of Delaware, Case No. 1:21-cv-00003, Covis Pharma GmbH v. Eugia Pharma Specialties Ltd.
